Relay Therapeutics (RLAY) Common Equity (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Common Equity of $642.2 million for Q1 2026, down 10.94% year-over-year from $721.1 million in Q1 2025, and up 13.25% quarter-over-quarter from $567.1 million in Q4 2025.
Relay Therapeutics (RLAY) Common Equity (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Common Equity for 8 consecutive years, with $642.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 10.94% year-over-year to $642.2 million; the TTM figure through Mar 2026 stood at $642.2 million (down 10.94% YoY), while the FY2025 annual figure was $567.1 million, down 27.09% from the prior year.
- Common Equity improved to $642.2 million in Q1 2026 per RLAY's latest filing, from $567.1 million in the prior quarter.
- Across five years, Common Equity topped out at $999.8 million in Q3 2022 and bottomed at $567.1 million in Q4 2025.
- Historically, Common Equity has averaged $767.3 million across 5 years, with a median of $777.8 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 75.06% — and 2025, when it retreated 27.56%.
- Relay Therapeutics' Common Equity stood at $950.2 million in 2022, then dropped by 20.86% to $752.0 million in 2023, then grew by 3.43% to $777.8 million in 2024, then decreased by 27.09% to $567.1 million in 2025, then grew by 13.25% to $642.2 million in 2026.
- Business Quant data shows RLAY's Common Equity at $642.2 million in Q1 2026, $567.1 million in Q4 2025, and $607.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 890.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 890.01 Mn |
| Mar 31, 2026 | 642.18 Mn |
| Dec 31, 2025 | 567.06 Mn |
| Sep 30, 2025 | 607.71 Mn |
| Jun 30, 2025 | 665.66 Mn |
| Mar 31, 2025 | 721.08 Mn |
| Dec 31, 2024 | 777.79 Mn |
| Sep 30, 2024 | 838.86 Mn |
| Jun 30, 2024 | 681.74 Mn |
| Mar 31, 2024 | 745.76 Mn |
| Dec 31, 2023 | 752.00 Mn |
| Sep 30, 2023 | 778.37 Mn |
| Jun 30, 2023 | 810.12 Mn |
| Mar 31, 2023 | 883.41 Mn |
| Dec 31, 2022 | 950.22 Mn |
| Sep 30, 2022 | 999.77 Mn |
| Jun 30, 2022 | 779.64 Mn |
| Mar 31, 2022 | 841.97 Mn |
| Dec 31, 2021 | 897.81 Mn |
| Sep 30, 2021 | 571.09 Mn |